Viread and Baraclude are expecting a competition against generics

The benefit range of the chronic hepatitis type B treatment ‘Viread (generic name: tenofovir)’ has been extended. This would be a favorable condition for the product prior to competition against its competing drug ‘Baraclude (generic name: entecavir)’ that will be poured out into the market next year. The joint prescription of ‘Zeffix (generic name: lamivudine)’ and ‘Hepsera (generic name: adef...